ClinicalTrials.gg
RecruitingNCT07436728Updated Oct 28, 2026

A Study of TAK-505 in Adults With Solid Tumors

A Phase 1/2 interventional study of TAK-505 in Malignant Solid Tumors, sponsored by Takeda. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Takeda · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 28, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable).

This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC).

The main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).

02

Conditions studied

  • Malignant Solid Tumors

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Aged greater than or equal to (≥) 18 years or ≥ the local legal age of majority, as applicable, at the time of signing the main form (ICF).
  2. Criteria for disease state in dose escalation and cohort-expansion:

    1. Tumor histologies during dose escalation (including potential participants in backfill cohort): Participants with or pathologically confirmed locally advanced or solid tumors, who are either ineligible for or intolerant of standard therapies, have no approved therapy with demonstrated benefit available, or have exhausted all available standard therapies:

<!-- -->

  1. Gastric adenocarcinoma.
  2. Colorectal cancer (CRC).
  3. Non-small cell lung cancer (NSCLC) (both squamous and non-squamous).
  4. Head and neck squamous cell carcinoma (HNSCC). b) Tumor histologies during dose expansion: Participants will be eligible if they have histologically or pathologically confirmed, locally advanced or metastatic solid tumors, as follows:

1. Metastatic or advanced squamous or non-squamous NSCLC:

  • Participants with no known activating mutations: have received platinum-based chemotherapy and anti-programmed death protein 1 ()/programmed death ligand 1 (PD-L1) for locally advanced or metastatic disease (chemotherapy and anti-PD-1/PD-L1 treatment can be received in combination or in sequence).
  • Participants with a known activating mutation with an approved and accessible target therapy (including but not limited to epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase, ROS proto-oncogene 1, receptor tyrosine kinase, v-raf murine sarcoma viral oncogene homolog B1V600, rearranged during transfection, mesenchymal epithelial transition [MET] exon 14 skipping mutation, neurotrophic tyrosine receptor kinase, and kirsten rat sarcoma G12C) should have received the respective targeted therapy and 1 line of platinum-based chemotherapy and anti-PD-1/PD-L1 (if appropriate).
  • Participants should have received no more than 3 for locally advanced or metastatic cancer.

    2. CRC: adenocarcinoma

  • Participants who have received or been intolerant to treatment with either trifluridine/tipiracil (TAS-102), regorafenib or fruquintinib. Participants who have been treated with all are permitted. Participants must also have been previously treated with standard approved therapies, such as: fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if rat sarcoma (RAS) wild-type, an anti-EGFR therapy or checkpoint inhibitors, as clinically appropriate.
  • Participants should have received no more than 4 prior lines of therapies for locally advanced or metastatic cancer.

    3. Gastric adenocarcinoma

  • Participants who have received or been intolerant to platinum/fluoropyrimidine doublet with or without anthracycline. Participants who are human epidermal growth factor receptor 2 () positive, PD-L1 positive or having microsatellite instability-high (MSI-H) should have received anti-HER2 and anti-PD-1/PD-L1 treatment, respectively.
  • Participants should have received no more than 3 prior lines of therapies for locally advanced or metastatic cancer.

    3. Confirmed PD-L1 positive by an FDA approved, Conformité Européene (CE)-marked, or other health-authority equivalent test in local lab. If historical PD-L1 status is not available, participants are eligible for pre-screening.

    4. Tumor tissue: All participants must provide an existing formalin-fixed paraffin-embedded (FFPE) taken within 24 months of the date of the main ICF. If the acquisition of FFPE blocks is not feasible, freshly cut slides from the eligible FFPE sample should be provided, and the slides need to have been cut within 3 months before the expected (Cycle 1 Day 1) C1D1. See the lab manual, which is provided separately, for further details. If an FFPE archival tumor sample is not available, tumor biopsy will be required before trial entry.

    5. (ECOG) performance status of 0 or 1. 6. Participants must have at least 1 lesion that meets the definition of by (RECIST) v1.1 criteria (radiologically measured by the investigator). Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable/target lesions, unless treatment was ≥12 months prior to start of treatment and/or there has been demonstrated progression in that particular lesion.

    7. Adequate bone marrow function as defined below:

    1. (ANC) ≥1,000/ microliters(μL),
    2. count ≥75,000/μL
    3. ≥9.0 grams per deciliter (g/dL). 8. Adequate renal and liver function as defined below:

    <!-- -->

    1. (ALT)/ Aspartate aminotransferase (AST) less than equal to (≤) 3.0 × the (ULN); for participants with hepatic metastases, ALT and AST)≤5 × ULN.
    2. Total ≤1.5 × ULN, except for participants with Gilbert's syndrome, who may be enrolled if the conjugated bilirubin is within normal limits.
    3. ≥45 mL/minute (calculated by Cockcroft-Gault formula). 9. toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute [NCI] [CTCAE] v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or endocrinopathies with stable endocrine replacement therapy.

      10. Suitable venous access for the collection of trial-required blood sampling. 11. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥14 days, and meet the following criteria at the time of enrollment:

    a) No concurrent treatment for CNS disease (for example, surgery, radiation, and ≥10 mg/d prednisone or equivalent).

    b) No concurrent or cord compression. Exclusion Criteria

    1. History of known autoimmune disease, except for:

      a) Vitiligo. b) Psoriasis not requiring systemic treatment for >1 year before receipt of TAK-505.

      c) History of Graves' disease in participants now euthyroid for >4 weeks. d) Hypothyroidism managed by thyroid hormone replacement. e) Alopecia. f) Well-controlled diabetes type 1.

    2. History of or leptomeningeal disease unless:

      a) Brain metastases are stable on cranial imaging (that is, ≥4 weeks) following prior surgery, whole-brain radiation OR b) Received stereotactic radiosurgery and is off corticosteroids for brain metastases AND c) Is without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).

    3. History of any of the following ≤6 months before the first dose of trial intervention:

      a) Congestive heart failure (NYHA) Grade III or IV. b) Unstable angina. c) Myocardial infarction. d) Unstable symptomatic ischemic heart disease. e) Uncontrolled hypertension despite appropriate medical therapy. f) Any ongoing symptomatic cardiac arrhythmias of Grade greater than (>) 2 (including acute atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia). Chronic, stable atrial fibrillation on stable anticoagulant therapy, including lowmolecular-weight heparin, is allowed.

      g) Acute symptomatic pulmonary embolism, or symptomatic cerebrovascular events, or any other serious cardiac condition (for example, pericardial effusion or restrictive cardiomyopathy).

      h) (LVEF) less than (\<) 50%, as measured by echocardiogram or multigated acquisition scan (MUGA) within 4 weeks before receiving the first dose of trial intervention.

    4. History of hepatic encephalopathy.
    5. Active diagnosis of a lung condition including:

      a) Pneumonitis b) Interstitial lung disease c) Severe d) Idiopathic pulmonary fibrosis e) Other restrictive lung diseases f) Acute symptomatic pulmonary embolism g) Grade ≥2 pleural effusion not controlled by tap or requiring indwelling catheters.

    6. Ongoing or active infection of Grade ≥2
    7. Oxygen saturation \<90% on room air at screening or during the C1D1 predose assessment.
    8. Inflammatory process that has not resolved for ≥4 weeks before the first dose of trial intervention. Participants with chronic low-grade inflammatory processes such as radiation induced pneumonitis are excluded regardless of duration.
    9. Clinically significant gastrointestinal disorders including the following:

      1. Gastrointestinal perforation or unhealed ulcerations \<6 months before trial intervention administration. Participants must have documented evidence (for example, upper endoscopy or colonoscopy) of a completely healed area of prior perforation.
      2. Gastrointestinal bleeding \<2 months before trial intervention administration. Participants must have documented evidence (for example, from upper endoscopy or colonoscopy) of a completely healed area of prior bleeding.
      3. Pancreatitis \<6 months before the initiation of trial intervention. Participants must have a computed tomography (CT) scan that is negative for evidence of remaining disease or normal pancreatic enzyme levels >4 weeks before the initiation of trial intervention.
      4. Diverticulitis flare \<2 months before trial intervention administration. Participants must have a CT scan demonstrating no evidence of remaining disease before the initiation of trial intervention.
      5. History of Crohn's disease or ulcerative colitis.
    10. Vaccination with any within 4 weeks or other vaccines within 2 weeks before the initiation of trial intervention. Inactivated annual influenza vaccination is allowed.
    11. History of a bone marrow transplantation within the past 5 years or solid organ transplantation (as a recipient) and use of agents.
    12. Known to TAK-505 or any (acetate, arginine, histidine, methionine or polysorbate 80) contained in the drug or diluent formulation, or known hypersensitivity to tocilizumab.
    13. Diagnosed with a second primary invasive not in remission for ≥3 years.

      Exceptions include:

      1. Nonmelanoma skin cancer
      2. Cervical carcinoma in situ
      3. Resected melanoma in situ
      4. Malignancies considered indolent and never required therapy. This does not include lymphomas.
      5. Others upon consultation and approval from the sponsor.
    14. Known to be (HIV) positive or or C positive as defined below:

      1. Positive serology for HIV.
      2. Positive hepatitis B surface antigen (HBsAg) test.
      3. Positive virus (HCV) antibody test.
    15. Received the following prior therapies before the planned start of TAK-505:

      1. Cytotoxic chemotherapy, small-molecule inhibitors, cell therapy, radiation, interventional radiology procedure, or similar therapies within ≤2 weeks or 5 half-lives, whichever is shorter.
      2. Monoclonal antibodies including PD-1 checkpoint inhibitors (for example, pembrolizumab and nivolumab), antibody (Ab)-drug conjugates, radioimmunoconjugates, or similar therapies within ≤4 weeks.
      3. Any anti-PD-L1 treatment, including PD-L1 checkpoint inhibitors (for example, atezolizumab and durvalumab) and antibody-drug conjugates, within 120 days.
      4. Not recovered to Grade 1 or baseline or established as sequelae from all toxic effects of previous therapy (except alopecia, neuropathy, or autoimmune endocrinopathies with stable endocrine replacement therapy, or bone marrow parameters [any of Grade 1/2 permitted if directly related to bone marrow involvement]).
    16. Used corticosteroids or other immunosuppressive medication, concurrently or within 14 days of administration of TAK-505, except for:

      a) Topical, intranasal, inhaled, ocular, or intra-articular corticosteroids. b) Physiologic doses of replacement steroid (for example, for adrenal insufficiency).

      c) Steroid premedication for hypersensitivity reactions and antiemetic use. d) Stable steroid dose (established for ≥28 days before the first dose of TAK-505) for previously treated brain metastasis. Corticosteroid dose on C1D1 should be ≤15 mg/d of prednisone or equivalent.

    17. Major surgery or traumatic injury within 8 weeks before the first dose of trial intervention.
    18. Unhealed wounds from surgery or injury.
    19. Any pre-existing medical or psychiatric condition or illness, metabolic dysfunction, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug or that would limit compliance with trial requirements or compromise ability to provide written informed consent.
    20. Has a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of trial intervention.
    21. Is capable of breastfeeding but does not agree to forego breastfeeding from the first dose of trial intervention through 180 days after the last dose of trial intervention.
    22. Is a person of (POCBP) but does not agree to use at least 1 form of highly effective and 1 barrier method of contraception (preferably male condom) until 180 days after the last dose of trial intervention. Contraception methods may be considered highly effective if they can achieve a failure rate of \<1% per year when used consistently and correctly.
    23. Is of male birth and fertile, and has partners of childbearing potential, but does not agree to use effective barrier contraception, that is, a condom, combined with at least 1 other form of acceptable contraception from signing of the main ICF until at least 180 days after the last dose of trial intervention.
    24. Does not agree to refrain from donating gametes from signing of the main ICF until 180 days after the last dose of trial intervention.
    25. Is a trial site employee, a site employee's immediate family member (for example, spouse, parent, child, and sibling), or is in a dependent relationship with a trial site employee who is involved in the conduct of this trial or may consent under duress.
    26. Is considered to be vulnerable, as defined per local regulations and if exclusion is required by local regulations. Examples are persons under safeguard of justice, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care without their consent, persons admitted to a health or social establishment for purposes other than research, persons of full age who are subject to a legal protection measure (guardianship or curatorship), and persons unable to express their consent.
    27. Is unable or unwilling to comply with clinic visits and procedures outlined in the trial protocol.
    28. Is unwilling to provide informed consent/age-appropriate assent.
    29. Baseline prolongation of the with Fridericia correction method (QTcF) (for example, repeated demonstration of corrected QT interval [QTc] ≥480 ms, history of congenital long QT syndrome, or torsades de pointes). If patients are taking medications known to prolong the QTc at screening, patients may continue to take these medications as long as their baseline QTcF is \<480 ms that are receiving such medications. Participants may not start using such medications on C1D1.
Terms in these criteria, in plain language(38)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
151 participants (estimated)

Study arms

  • Experimental
    Phase 1: TAK-505 Dose Escalation

    Participants will receive TAK-505 intravenous (IV) infusion until disease progression intolerability, or any other treatment discontinuation criterion is met.

    Drug: TAK-505

  • Experimental
    Phase 2: TAK-505 Dose Expansion

    Participants with up to 3 selected tumor indications will receive the recommended dose for expansion (RDE) until disease progression intolerability, or any other treatment discontinuation criterion is met.

    Drug: TAK-505

Interventions

  • DrugTAK-505

    Participants will receive TAK-505 intravenously (IV)

06

What researchers measure

Primary outcomes

  1. Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLTs are defined as specific Grade 3 and 4 hematologic and hepatic nonhematologic events or any other Grade ≥3 adverse events related to treatment that occur during the DLT evaluation period after administration of TAK-505, except events that are clearly due to the underlying disease or an extraneous cause.

    Time frame: From initial dose until 28 days after infusion of the first cohort dose on Cycle 1 Day 1

  2. Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Clinically Significant Laboratory Values and Vital Signs

    An Adverse Event (AE) is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of TAK-505, whether or not the occurrence is considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of TAK 505. TEAEs that occur after administration of the first dose of trial intervention and through 30 days after the last dose of trial intervention will be tabulated.

    Time frame: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)

  3. Phase 2 Dose Expansion: Confirmed Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve partial response (PR) or complete response (CR), as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Up to end of study (up to approximately 52 months)

  4. Phase 2 Dose Expansion: Number of Participants With TEAEs, Clinically Significant Laboratory Values and Vital Signs

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of TAK-505, whether or not the occurrence is considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of TAK 505. TEAEs that occur after administration of the first dose of trial intervention and through 30 days after the last dose of trial intervention will be tabulated.

    Time frame: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)

Secondary outcomes

  1. Phase 1 and Phase 2: Maximum Observed Concentration (Cmax) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and end of infusion (EOI) except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; End of treatment (EOT) (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  2. Phase 1 and Phase 2: Time to Maximum Concentration (tmax) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and EOI except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; EOT (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  3. Phase 1 and Phase 2: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC0-last) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and EOI except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; EOT (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  4. Phase 1 and Phase 2: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and EOI except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; EOT (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  5. Phase 1 and Phase 2: Terminal Phase Half-Life (t1/2z) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and EOI except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; EOT (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  6. Phase 1 and Phase 2: Total Clearance After Intravenous Administration (CL) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and EOI except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; EOT (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  7. Phase 1 and Phase 2: Volume of Distribution at Steady State After Intravenous Administration (Vss) of TAK-505

    The cycle length for each cycle is 28 days.

    Time frame: Phase 1, all cycles: pre-dose and EOI except Cycles 1 and 3: Day1-pre-dose and post dose up to 168 hours; Day 15-pre-dose and EOI; EOT (up to 7 months); Phase 2, all Cycles: pre-dose, EOI and EOT (up to 9 months)

  8. Phase 1: Confirmed ORR

    ORR is defined as the percentage of participants who achieve PR or CR, as assessed by the investigator, per RECIST v 1.1.

    Time frame: Up to end of study (up to approximately 52 months)

  9. Phase 1 and Phase 2: Duration of response (DOR)

    DOR is defined as the duration from the date of first documented confirmed PR or confirmed CR to the date of first documented progressive disease (PD) or death, whichever occurs first.

    Time frame: From first dose until disease progression or death (up to approximately 52 months)

  10. Phase 1 and Phase 2: Progression free survival (PFS)

    PFS is defined as the duration from the date of first dose administration to the date of first documentation of PD or death, whichever occurs first.

    Time frame: From first dose until disease progression or death (up to approximately 52 months)

  11. Phase 1 and Phase 2: Overall survival (OS)

    OS is defined as the duration from the date of the first dose administration to the death. Participants without documentation of death will be censored at the date last known to be alive.

    Time frame: From first dose until death (up to approximately 52 months)

  12. Phase 1 and Phase 2: Disease control rate (DCR)

    DCR is defined as the percentage of participants who achieve stable disease (SD) for longer than 12 weeks, PR or CR, as assessed by the investigator, per RECIST version 1.1

    Time frame: From first dose until disease progression or death (up to approximately 52 months)

  13. Phase 1 and Phase 2: Time to response (TTR)

    TTR is defined as the duration from the date of first dose administration to the date of first documented confirmed PR or confirmed CR.

    Time frame: From first dose until first documented response up to end of treatment (up to approximately 52 months)

  14. Phase 1 and Phase 2: Number of Participants Who Are Antidrug Antibody (ADA)-Positive

    Time frame: From Baseline through end of treatment visit (30 days after administration of the last dose (up to approximately 52 months)

  15. Phase 1 and Phase 2: Number of Participants With Change in Magnitude of ADA Response

    Time frame: From Baseline through end of treatment visit (30 days after last dose) (up to approximately 52 months)

  16. Phase 2 Dose Expansion: Number of Participants With CD8 T-Cell Infiltration in the Tumor Microenvironment

    The T-cell infiltration levels will be calculated as a change from pre-treatment to post-treatment levels. Number of participants who express increase in T-cell infiltration levels between the pre-treatment and post-treatment tumor biopsies will be reported.

    Time frame: From screening (within 28 days of the first dose of TAK-505), and then every 56 days (±5 days) from the first dose of TAK-505, and at end of treatment (up to approximately 52 months)

07

Study locations

13 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Aug 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 27, 2026
StartActual
May 11, 2026
Primary completionEst.
Aug 18, 2030
CompletionEst.
Aug 18, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • University of California San Francisco · San Francisco, United StatesNot yet recruiting→Recruiting
  • Icahn School of Medicine at Mount Sinai · New York, United StatesNot yet recruiting→Recruiting
  • Cleveland Clinic Foundation · Cleveland, United StatesNot yet recruiting→Recruiting
  • Baylor College of Medicine · Houston, United StatesNot yet recruiting→Recruiting
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Baylor College of Medicine · Houston, United StatesContact person changed (no phone or email listed)Contact •••3750→•••6500Contact b•••@bcm.edu→m•••@bcm.edu
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • University of California San Francisco · San Francisco, United StatesNot yet recruiting→Recruiting
    • Icahn School of Medicine at Mount Sinai · New York, United StatesNot yet recruiting→Recruiting
    • Cleveland Clinic Foundation · Cleveland, United StatesNot yet recruiting→Recruiting
    • Baylor College of Medicine · Houston, United StatesNot yet recruiting→Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Baylor College of Medicine · Houston, United StatesContact person changed (no phone or email listed)Contact •••3750→•••6500Contact b•••@bcm.edu→m•••@bcm.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07436728
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
May 11, 2026
Primary completion
Aug 18, 2030 (estimated)
Completion
Aug 18, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion